New research is building a compelling case that the shingles vaccine may do far more than protect against a painful viral illness.
Studies involving hundreds of thousands of older adults suggest that vaccination is associated with significantly reduced rates of dementia diagnosis over time.
Research from Stanford University indicates the shingles shot may prevent or delay dementia and slow cognitive decline in people already experiencing memory problems.
Among large populations of older adults in Wales and Australia, those vaccinated against shingles were 20% less likely to develop dementia than unvaccinated people over the following seven years.
A separate study of more than 500,000 people found that recipients of the Shingrix shingles vaccine were 24% less likely to be diagnosed with dementia over four years.
Researchers estimate that roughly one dementia case could be prevented for every 17 people who receive the vaccine, a striking figure that has captured widespread attention.
A large-scale study of 1.5 million Medicare beneficiaries found the two-dose Shingrix series linked to a 33% lower risk of dementia in adults over age 65.
That same study found the recombinant zoster vaccine associated with a 28% reduced risk of Alzheimer’s disease and a 33% lower risk of vascular dementia compared to unvaccinated individuals.
The recombinant vaccine was also specifically tied to a 17% increase in diagnosis-free time, translating into 164 additional days lived without a dementia diagnosis among those subsequently affected.
Adults with no prior memory problems who received the shingles vaccine had a 3.1-percentage-point lower risk of developing mild cognitive impairment over nine years versus those who did not.
Among people already living with dementia, vaccination was linked to a 29.5-percentage-point lower chance of dying from dementia over that same nine-year period.
Researchers believe the benefit likely stems from how the vaccine stimulates the immune system broadly, rather than simply from stopping the shingles virus itself.
A key feature of Shingrix is an ingredient called AS01, an adjuvant specifically designed to produce a stronger immune response than older shingles vaccines.
Emerging evidence increasingly suggests that vaccines, including those for shingles and influenza, may promote healthy aging by modulating biological systems well beyond infection prevention.
One commentary published in Nature Medicine stated: “We have never had as robust a body of evidence from observational data on an intervention for dementia as we do for live-attenuated shingles vaccination.”
One behavioral sciences professor noted that she now tells people to talk to their doctor about the shingles vaccine alongside standard advice about exercise and staying socially active.
“There is no guarantee that doing these things means you will not get dementia, but all are relatively easy and accessible and help maintain healthy cognition for longer,” she said.
Most leading studies remain observational in nature, meaning they demonstrate a strong association between vaccination and reduced dementia risk without providing definitive causal proof.
Researchers note, however, that findings are consistent across multiple large studies conducted in different countries, strengthening confidence in the overall direction of the evidence.
The CDC currently recommends that adults aged 50 and older receive the two-dose Shingrix series, with the potential cognitive benefits now adding further weight to that guidance.
